Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el miércoles 18/06/2025 al final de la jornada laboral. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
179
resultados
Última actualización
21/06/2025 [07:57:00]
Resultados 125 a 150 de 179
Resumen de: US2025144296A1
Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.
Resumen de: US2025144295A1
Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.
Resumen de: US2025143609A1
An oxygen-independent analyte sensor includes at least one electrode and an oxygen-independent analyte sensing molecule disposed on the at least one electrode. The oxygen-independent analyte sensing molecule is electrografted on to the at least one electrode. The sensor may process an electrochemical impedance spectroscopy (EIS) parameter value in response to exposure to an analyte.
Resumen de: US2025143605A1
Provided are a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body.
Resumen de: US2025143606A1
Provided relates to a continuous blood glucose measurement device which is produced with an assembled body attachment unit inside an applicator so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body by simply activating the applicator, and which is provided with a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use, without additional work of connecting a separate transmitter, and easier maintenance; and is activated by the user after the body attachment unit is attached to the body so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Resumen de: EP4550344A1
A method for generating diabetes management parameter user interfaces includes providing stored program instructions of a first diabetes management application (DMA), the first DMA configured to be stored in a memory of an electronic device and, upon execution by a processor, the first DMA is configured to generate a first output display of a plurality of diabetes management parameters corresponding to a time series of analyte data, the plurality of diabetes management parameters depicting a trend of diabetes management parameter levels over time, generate a graphical indicator of a link to a second DMA stored in the memory, and activate the second DMA in response to an input selection of the link, wherein the second DMA is configured to be executed by the processor to generate a second output display of a current-time diabetes management parameter corresponding to the time series of the analyte data stored in the memory.
Resumen de: EP4548844A1
The present invention proposes a method of measuring the real-time level and degree of management of blood sugar based on an electrocardiogram. The method includes: obtaining an electrocardiogram signal measured for a user; estimating the user's blood sugar level by analyzing the electrocardiogram signal using a pre-trained first artificial intelligence, and determining whether the user has hyperglycemia or hypoglycemia by analyzing the electrocardiogram signal using an artificial intelligence; and determining whether the user needs guidance on blood sugar or diabetes based on the estimated blood sugar level and the result of the determination of whether the user has hyperglycemia or hypoglycemia. Through this, a user may check the user's immediate blood sugar level and how well the blood sugar is managed simply by measuring the electrocardiogram 10, and as a result, hyperglycemia and diabetes may be detected early or a complication attributable to hyperglycemia or diabetes may be prevented.
Resumen de: EP4550348A1
Systems and methods for glucose device batch analyses. An example method includes obtaining analysis datasets reflecting manufacturing information associated with medical devices included in a device batch, the manufacturing data measuring information associated with individual manufacturing steps, and with the analysis datasets being formatted for input into a machine learning model, and with unique identifying information associated with the medical devices being used to aggregate analysis datasets specific to the medical devices. The analysis datasets are provided to the machine learning model, with the machine learning model being trained to output performance information for individual medical devices indicating whether they are in releasable condition. The machine learning model was trained based on ground truth associated with manufactured devices, and the ground truth was derived based on test information associated with the manufactured devices. An interactive user interface is generated which presents summary information associated with the performance information.
Resumen de: EP4548898A1
A body surface ulcer healing promotion device is provided, which includes: a glucose concentration sensor 11 that detects a glucose concentration in an exudate from an ulcer 2 on a body surface 1; vibrators 21A, 21B, 21C that apply vibration to the ulcer 2; and a control device 31 that controls the vibration of the vibrators 21A, 21B, 21C on a basis of the glucose concentration in the exudate.
Resumen de: WO2025090855A1
Provided are a method, system, and computer-readable medium for personalizing titration measurement for basal insulin dosing. The personalization can be achieved using spare self-monitoring blood glucose (SMBG) and/or dense continuous glucose monitoring (CGM) data to predict a fasting blood glucose (FBG) envelope accounting for online estimation of titration noise representative of variability in daily fasting measurement. As a result, basal insulin dosing directed to causing the FBG envelope to be maintained for an optimal glycemic range can then be obtained.
Resumen de: WO2025090951A1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational Al model. The conversational Al model is configured to drive a conversational Al agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
Resumen de: WO2025086630A1
Disclosed are a postprandial insulin infusion system and method based on recognizable features of a diabetic patient. A food image is acquired by an imaging module, and the food image is analyzed by a food image recognition model to obtain food data. According to the recognizable features of the patient, a narrow-sense insulin algorithm adapted to the recognizable features of the patient is retrieved from a narrow-sense insulin algorithm cluster and used for calculating an insulin infusion amount during the meal. Compared with a preset insulin algorithm, the narrow-sense insulin algorithm is more adapted to the physiological characteristics and living habits of the patient, and the calculated postprandial insulin infusion amount is more accurate, which is conducive to the treatment of diabetes in the patient.
Resumen de: WO2025086631A1
Disclosed in the present invention are a closed-loop infusion system and method based on food image recognition. A food image is acquired by an imaging module, and the food image is analyzed by a food image recognition model to obtain food data. An insulin algorithm determines a postprandial insulin infusion amount for a patient on the basis of the food data and simulates postprandial blood glucose for the patient. While infusing insulin, an artificial pancreas collects real-time blood glucose data. The real-time blood glucose data are compared with the simulated blood glucose data, and the comparison result is used for correcting parameters of the insulin algorithm, making the insulin algorithm more suitable for the patient. The present invention improves the accuracy and adaptability of the insulin algorithm, which is conducive to the treatment of diabetes in the patient.
Resumen de: US2025134463A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: AU2023372542A1
Embodiments can relate to a system for automatically detecting sensor compression in continuous glucose monitoring including at least one sensor and at least one processor in communication with the at least one sensor, the at least one processor executing at least two machine learning models, wherein the at least one processor is programmed or configured to cause the processor to receive, from the at least one sensor, measurement data including at least one time series of blood glucose (BG) measurements measured by the at least one sensor, determine that the at least one time series of BG measurements is a candidate series including a compression artifact using a first machine learning model, and generate, using a second machine learning model, a signal output indicating that the at least one time series of BG measurements was obtained while the at least one sensor was subject to compression.
Resumen de: US2025134419A1
Provided relates to a continuous blood glucose measurement device which is produced with an assembled body attachment unit inside an applicator so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body by simply activating the applicator, and which is provided with a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use, without additional work of connecting a separate transmitter, and easier maintenance; and is activated by the user after the body attachment unit is attached to the body so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Resumen de: US2025134417A1
A processor-implemented method includes receiving sensor measurement data from a glucose sensor; selecting, based on the sensor measurement data, a first regional sensor glucose (SG) model from a first plurality of regional SG models for respective regions of a first plurality of regions of an input parameter space associated with the sensor measurement data, and a second regional SG model from a second plurality of regional SG models for respective regions of a second plurality of regions of the input parameter space; estimating a first SG value and a second SG value using the first regional SG model and the second regional SG model, respectively; and determining a predicted SG value based on a combination of the first SG value and the second SG value. The input parameter space is partitioned into the first plurality of regions and the second plurality of regions using different partition schemes.
Resumen de: US2025134381A1
A biometric wearable device (e.g. finger ring or smart watch) has optical sensors to measure body oxygenation level, hydration level, glucose level, heart rate, heart rate variability, and/or blood pressure. Light from light emitters is transmitted through body tissue and changes in the light are analyzed. In an example, the device can include body-facing protrusions where the light emitters and/or the light receivers are located.
Resumen de: US2025140393A1
Systems and methods for glucose device batch analyses. An example method includes obtaining analysis datasets reflecting manufacturing information associated with medical devices included in a device batch, the manufacturing data measuring information associated with individual manufacturing steps, and with the analysis datasets being formatted for input into a machine learning model, and with unique identifying information associated with the medical devices being used to aggregate analysis datasets specific to the medical devices. The analysis datasets are provided to the machine learning model, with the machine learning model being trained to output performance information for individual medical devices indicating whether they are in releasable condition. The machine learning model was trained based on ground truth associated with manufactured devices, and the ground truth was derived based on test information associated with the manufactured devices. An interactive user interface is generated which presents summary information associated with the performance information.
Resumen de: AU2023372535A1
Embodiments can relate to systems and methods for automatically detecting sensor compression in continuous glucose monitoring in real time. A system may include at least one sensor and at least one processor in communication with the at least one sensor. The at least one processor is programmed or configured to cause the processor to retrieve first measurement data including at least one time series of blood glucose (BG) measurements, the at least one time series being measured by the at least one sensor while not subject to compression; receive, from the at least one sensor, second measurement data including at least one BG measurement; determine a clearance value between BG measurements based on the first measurement data and the second measurement data; and generate a signal output indicating that the at least one sensor is subject to compression based on the clearance value between BG measurements exceeding a predefined threshold.
Resumen de: US2025134416A1
Techniques disclosed herein relate to glucose level measurement and/or management. In some embodiments, the techniques involve obtaining in vivo characteristics of a glucose sensor predicted using fabrication process measurement data associated with the glucose sensor, the in vivo characteristics including an in vivo sensitivity, an in vivo intercept, or a combination thereof; receiving sensor measurement data measured by the glucose sensor, the sensor measurement data including sensor current (Isig), counter voltage (Vcntr), electrochemical impedance spectroscopy (EIS) data, an age of the glucose sensor, or a combination thereof; and estimating a sensor glucose (SG) value using an SG model, wherein input parameters of the SG model include the in vivo characteristics of the glucose sensor and the sensor measurement data, and the SG value is an output of the SG model.
Resumen de: MD1834Y
The invention relates to medicine, namely to cardiology, and can be used for predicting, based on clinical parameters, the risk of hospitalization for heart failure during the first year after myocardial revascularization.Summary of the invention consists in that the patient's age and gender are indicated, the duration of ischemic heart disease, the presence of diabetes mellitus, the presence of a previous myocardial infarction and left ventricular aneurysm detected early after an acute event are determined, a blood test is performed to determine serum creatinine and the glomerular filtration rate is calculated using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula to assess the stage of chronic kidney disease, the Charlson comorbidity index and the duration of hospitalization for an acute cardiac event with myocardial revascularization by coronary artery bypass grafting or percutaneous coronary angioplasty are determined, then the discriminant function (F) is calculated using the formula:F = -4.266 + G · 0.386 - V · 0.008 + DBCI · 0.099 + DZ · 0.459 + BCR · 0.389 - IMV · 0.733 + CCI · 0.459 + AVS · 1.974 + DMRev · 0.094, where:G - gender: 1 - female,2 - male;V - age, expressed in years (18...100 years);DBCI - duration of coronary heart disease, expressed in years (0...50 years);DZ - diabetes mellitus: 0 - absent,1 - present;BCR - stage of chronic kidney disease according to KDIGO classification: 1- G1:RFG ≥ 90,2- G2:RFG = 60...89,3- G3a,b:RF
Resumen de: EP4545001A1
A diabetes risk detection method, an electronic device, and a system are disclosed and are applied to the field of terminal technologies, to resolve a problem in the conventional technology that an obtained diabetes risk detection result is inaccurate when time for collecting a PPG signal is short. The method includes: obtaining first data and second data, where the first data includes a photoplethysmography PPG signal obtained via a PPG sensor, and the second data includes one or more of the following: diet data, exercise data, physical symptom data, drug use data, sleep data, and emotion data; determining a diabetes risk detection result based on the first data and the second data; and finally outputting the diabetes risk detection result to prompt a user with a health status.
Resumen de: EP4545002A1
A processor-implemented method includes receiving sensor measurement data from a glucose sensor; selecting, based on the sensor measurement data, a first regional sensor glucose (SG) model from a first plurality of regional SG models for respective regions of a first plurality of regions of an input parameter space associated with the sensor measurement data, and a second regional SG model from a second plurality of regional SG models for respective regions of a second plurality of regions of the input parameter space; estimating a first SG value and a second SG value using the first regional SG model and the second regional SG model, respectively; and determining a predicted SG value based on a combination of the first SG value and the second SG value. The input parameter space is partitioned into the first plurality of regions and the second plurality of regions using different partition schemes.
Nº publicación: EP4546359A2 30/04/2025
Solicitante:
INSULET CORP [US]
Insulet Corporation
Resumen de: EP4546359A2
A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.
BOPI
Sede Electrónica
